Lenvatinib Capsules — Competitive Intelligence Brief

Lenvatinib Capsules (Lenvatinib Capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-targeted tyrosine kinase inhibitor. Area: Oncology.

phase 3 Multi-targeted tyrosine kinase inhibitor FGFR1-4, VEGFR1-3, RET, KIT, PDGFR-alpha Oncology Small molecule

Target snapshot

Lenvatinib Capsules (Lenvatinib Capsules) — National Cancer Institute, Naples. Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and other kinases to inhibit tumor angiogenesis and growth.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lenvatinib Capsules TARGET	Lenvatinib Capsules	National Cancer Institute, Naples	phase 3	Multi-targeted tyrosine kinase inhibitor	FGFR1-4, VEGFR1-3, RET, KIT, PDGFR-alpha
Lenvatinib + losartan	Lenvatinib + losartan	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist	FGFR, VEGFR, RET (lenvatinib); AT1 receptor (losartan)
Anlotinib hydrochloride capsules	Anlotinib hydrochloride capsules	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, FGFR, PDGFR, c-Kit, RET
Sunitinib (Sutent)	Sunitinib (Sutent)	Sponsor GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, PDGFR, KIT, FLT3
pazopanib or guideline conform chemotherapy	pazopanib or guideline conform chemotherapy	GWT-TUD GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit
Sunitinib Malate (SU011248)	Sunitinib Malate (SU011248)	H. Lee Moffitt Cancer Center and Research Institute	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, PDGFR, KIT, FLT3
Letybo®	Letybo®	Yuvell	marketed	FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor	FLT3, JAK2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-targeted tyrosine kinase inhibitor class)

1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
2. Exelixis · 2 drugs in this class
3. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. National Cancer Institute, Naples · 1 drug in this class
6. Sponsor GmbH · 1 drug in this class
7. Sun Yat-sen University · 1 drug in this class
8. TransThera Sciences (Nanjing), Inc. · 1 drug in this class
9. Advenchen Laboratories Nanjing Ltd. · 1 drug in this class
10. University of Wisconsin, Madison · 1 drug in this class